David Windley

“And pivoting for my follow-up, a lot of moving parts in China over the course of this year, maybe over the course of the last several years, regulatorily, drug development-wise, et cetera.”

“I'll forewarn you this is a multi-parter period. it. I'm interested in demand environment. You talked in the prepared remarks about pretty balanced demand and DSA across study types.”

“Seems like a meaningful part of it is pass-throughs. So I wanted to understand I guess on both sides the kind of progression of your customer cohorts. Large pharma sounds like it advanced a little bit.”

“I wanted to ask a clarification and then more of a content question. So the clarification, I think, Mike, you quantified two and a half percent of acquisition contribution.”

“August, I wanted to try to understand hearing you on the contingency backlog considerations that you had mentioned to me recently and mentioned again this morning and how influential they are.”